In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


Credit Designation Statement

AACR has designated this live activity for a maximum of 17.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Tuesday, December 1, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives

The field of immunotherapy is one of the most promising in cancer research. Utilizing the body’s immune system to fight cancer is often safer and better tolerated than traditional cancer treatments such as chemotherapy and radiation. Study and understanding of the immune system’s response to cancer has increased exponentially over the past several years, and this has given rise to many breakthrough cancer treatments.

Types of immunotherapies include radio- or chemolabeled monoclonal antibodies (including checkpoint inhibitors); bispecific monoclonal antibodies; checkpoint immunomodulators such as PD-1, PD-L1, and CTLA-4 inhibitors, which have been approved for treatment of many cancers; adoptive cell transfer (including CAR T cell therapy); therapeutic vaccines for treatment and prevention; cytokines such as interleukins and interferons; and oncolytic viruses.

Current promising research includes engineering strategies to improve the safety, efficacy and applicability of CAR T cell therapy for use in a wider range of malignancies; the discovery of novel therapeutic agents targeting innate cells and pathways that suppress anti-tumor immunity; next-generation single-cell approaches to resolve tumor heterogeneity; smart design and personalization for enhanced vaccines better able to infiltrate tumors; and the contribution of non-classical immune cells in immunogenicity and immunosurveillance. Research is also being conducted to identify biomarkers of immune-related adverse events (IRAEs), such as autoimmunity, neurotoxicity, colitis, and cardiovascular toxicities, while also attempting to understand correlation between IRAEs and response to immunotherapy. The end goal remains a deeper understanding of immunology and cancer in order to design better treatments.

Only through a thorough understanding of the basic immunological science behind these new technologies and collaboration between basic scientists and oncologists can new treatments be developed. For physicians to best aid patients, they must have a solid and current understanding of the complexities of basic immunotherapy and new advances taking place in the lab that can eventually be applied to the clinic. Physicians will leave this conference with knowledge of novel advancements in immunotherapy in the lab and the potential thereof for therapeutic applications

After participating in this CME activity, physicians should be able to:

  1. Identify novel approaches to immune engineering and synthetic biology.
  2. Evaluate novel biomarkers or neoantigens, and genetics to assess patients’ individual cancer, potential responses to treatment, and to personalize therapy.
  3. Evaluate T-cell and non-T-cell therapies to treat blood cancers and potentially to treat solid tumors.
  4. Assess innate and adaptive pathways to target with checkpoint therapies.
  5. Integrate novel combination and targeted therapies for personalizing cancer immune responses.
  6. Identify biomarkers of immune-related adverse events.
  7. Integrate next-generation single-cell analysis approaches to enhance immune activity and resolve tumor heterogeneity

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters:

Major Supporter

Bristol Myers Squibb

Professional Educational Grant

GlaxoSmithKline
Pfizer

Questions about CME?

Please contact the Office of CME at (215) 440-9300 or [email protected].